David Nayagam from E & P covers PYC. Has release a speculative buy note out today with a 24c valuation. He notes "developmental molecular therapies targeting monogenic conditions with clear genotypic-phenotypic associations enjoy tantalizingly high probabilities of success". Still adopts a conservative approach to the current valuation and ascribes zero value to the third and fourth pipeline assets (PM and PKD).
David Nayagam from E & P covers PYC. Has release a speculative...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.020(1.74%) |
Mkt cap ! $670.7M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.18 | $1.17 | $4.269K | 3.647K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 10256 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 10259 | 5 |
View Market Depth
| Last trade - 10.11am 19/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |